Norges Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Norges Bank’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-445,868	Closed	-$3.09M	–	1787
2024 Q4	$3.09M	Buy	+445,868	New	+$3.35M	﹤0.01%	1618
2021 Q3	–	Sell	-30,000	Closed	-$681K	–	2302
2021 Q2	$681K	Buy	+30,000	New	+$611K	﹤0.01%	2146

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Norges Bank's GLUE Position: Q1 2025 in Review

Norges Bank sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 445,868 shares — an estimated $3.09M sold.

Norges Bank first reported a position in GLUE in Q2 2021 and held it in 2 quarters. The position peaked at $3.09M in Q4 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

Norges Bank reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 445,868 Monte Rosa Therapeutics shares in Q1 2025, an estimated $3.09M.
Norges Bank first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 2 quarters.
Norges Bank's Monte Rosa Therapeutics position peaked at $3.09M in Q4 2024.
105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.